Herpes zoster in Belgium: a new solution to an old problem

References

• Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses. 2022;14(2):192. doi: 10.3390/v14020192
   PubMed Web of Science ®Google Scholar
• Pieters Z, Ogunjimi B, Beutels P, et al. Cost-effectiveness analysis of herpes zoster vaccination in 50- to 85-year-old immunocompetent Belgian cohorts: a comparison between no vaccination, the adjuvanted subunit vaccine, and live-attenuated vaccine. Pharmacoeconomics. 2022;40(4):461–476. doi: 10.1007/s40273-021-01099-2
   PubMed Web of Science ®Google Scholar
• Abbasi R, Abdou Y, Ackermann M, et al. Limits on a muon flux from neutralino annihilations in the sun with the IceCube 22-string detector. Phys Rev Lett. 2009;102(20):201302. doi: 10.1103/PhysRevLett.102.201302
   PubMed Web of Science ®Google Scholar
• Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8(1):37. doi: 10.1186/1741-7015-8-37
   PubMed Web of Science ®Google Scholar
• Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic Neuralgia: Epidemiology, Pathophysiology, and Pain Management Pharmacology. J Multidiscip Healthc. 2016;9:447–454. doi: 10.2147/JMDH.S106340
   PubMed Web of Science ®Google Scholar
• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. doi: 10.1136/bmjopen-2014-004833
   PubMed Web of Science ®Google Scholar
• Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81(10):928–930. doi: 10.1212/WNL.0b013e3182a3516e
   PubMed Web of Science ®Google Scholar
• Arvin AM. Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis. 2008;197(Suppl 2):S58–60. doi: 10.1086/522123
   PubMed Web of Science ®Google Scholar
• Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol. 2007;211(2):144–156. doi: 10.1002/path.2104
   PubMed Web of Science ®Google Scholar
• Tu W, Rao S. Mechanisms underlying T cell immunosenescence: aging and cytomegalovirus infection. Front Microbiol. 2016;7:2111. doi: 10.3389/fmicb.2016.02111
   PubMed Web of Science ®Google Scholar
• Fulop T, Larbi A, Dupuis G, et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2017;8:1960. doi: 10.3389/fimmu.2017.01960
   PubMed Web of Science ®Google Scholar
• Marra F, Parhar K, Huang B, et al. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7(1):ofaa005. doi: 10.1093/ofid/ofaa005
   PubMed Web of Science ®Google Scholar
• Din S, Selinger CP, Black CJ, et al. Systematic review with network meta-analysis: risk of herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57(6):666–675. doi: 10.1111/apt.17379
   PubMed Web of Science ®Google Scholar
• Dauby N, Motet C, Libois A, et al. The value of herpes zoster prevention in people aging with HIV: a narrative review. HIV Med. 2023;24(12):1190–1197. doi: 10.1111/hiv.13548
   PubMed Web of Science ®Google Scholar
• Zhou H, Wang Z, Jin H, et al. A systematic review and meta-analysis of independent risk factors for postherpetic neuralgia. Ann Palliat Med. 2021;10(12):12181–12189. doi: 10.21037/apm-21-3028
   PubMed Web of Science ®Google Scholar
• Forbes HJ, Thomas SL, Smeeth L, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2016;157(1):30–54. doi: 10.1097/j.pain.0000000000000307
   PubMed Web of Science ®Google Scholar
• Johnson RW, Alvarez-Pasquin M-J, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3(4):109–120. doi: 10.1177/2051013615599151
   PubMedGoogle Scholar
• Cohen EJ, Jeng BH. Herpes zoster: a brief definitive review. Cornea. 2021;40(8):943–949. doi: 10.1097/ICO.0000000000002754
   PubMed Web of Science ®Google Scholar
• Johnson BH, Palmer L, Gatwood J, et al. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis. 2015;15(1):502. doi: 10.1186/s12879-015-1262-8
   PubMedGoogle Scholar
• Pierik JG, Gumbs PD, Fortanier SA, et al. Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. BMC Infect Dis. 2012;12(1):110. doi: 10.1186/1471-2334-12-110
   PubMedGoogle Scholar
• Bardach AE, Palermo C, Alconada T, et al. Herpes zoster epidemiology in Latin America: a systematic review and meta-analysis. PLOS ONE. 2021;16(8):e0255877. doi: 10.1371/journal.pone.0255877
   PubMed Web of Science ®Google Scholar
• Roberfroid D, Zeevaert R, Maertens de Noordhout C, et al. Evaluation of shingrix vaccine against herpes zoster. Health Tech Ass (HTA) Brussels: Belgian Health Care Knowe Cen (KCE). 2022. KCE Reports 360. D/2022/. https://kce.fgov.be/sites/default/files/2022-10/KCE_360_Evaluation_Of_Vaccine_Against_Herpes_Report.pdf
   Google Scholar
• Kim YJ, Lee CN, Lee MS, et al. Recurrence rate of herpes zoster and its risk factors: a population-based cohort study. J Korean Med Sci. 2019;34(2):e1. doi: 10.3346/jkms.2019.34.e1
   PubMed Web of Science ®Google Scholar
• Bilcke J, Ogunjimi B, Marais C, et al. The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect. 2012;140(11):2096–2109. doi: 10.1017/S0950268811002640
   PubMed Web of Science ®Google Scholar
• Sabbe M, Grammens T, Braeye T, et al. Maladies infectieuses pédiatriques à prévention vaccinale. 2014. [cited 2023 Nov8]. Available from: https://www.sciensano.be/en/biblio/maladies-infectieuses-pediatriques-a-prevention-vaccinale-synthese-annuelle-2014
   Google Scholar
• Jacquinet S, Bensemmane S, Smeesters P, et al. Surveillance épidémiologique de la Varicelle et du Zona – varicella-zoster virus (VZV) – aperçu 2010-2022 et résultats détaillés 2019–2022. Sciensano. 2023:1–17.
   Google Scholar
• Bricout H, Perinetti E, Marchettini P, et al. Burden of herpes zoster-associated chronic pain in Italian patients aged 50 years and over (2009–2010): a GP-based prospective cohort study. BMC Infect Dis. 2014;14(1):637. doi: 10.1186/s12879-014-0637-6
   PubMedGoogle Scholar
• Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–1349. doi: 10.4065/82.11.1341
   PubMed Web of Science ®Google Scholar
• Gater A, Uhart M, McCool R, et al. The humanistic, economic and societal burden of herpes zoster in Europe: a critical review. BMC Public Health 2015;15(1):193. doi: 10.1186/s12889-015-1514-y
   PubMedGoogle Scholar
• Wauters O, Lebas E, Nikkels AF. Chronic mucocutaneous herpes simplex virus and varicella zoster virus infections. J Am Acad Dermatol. 2012;66(6):e217–27. doi: 10.1016/j.jaad.2010.07.011
   PubMed Web of Science ®Google Scholar
• Andrei G, Snoeck R. Advances and perspectives in the management of varicella-zoster virus infections. Molecules 2021;26(4):1132. doi: 10.3390/molecules26041132
   PubMed Web of Science ®Google Scholar
• Chen N, Li Q, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2014(2): CD006866. 10.1002/14651858.CD006866.pub3
   Google Scholar
• Belgian Antibiotic Policy Coordination Commission. Guide belge de traitement anti-infectieux en pratique ambulatoire 2022. [cited 2023 Nov 8]. https://organesdeconcertation.sante.belgique.be/sites/default/files/content/bapcoc_guide_traitement_antiinfectieux_2022.pdf
   Google Scholar
• McDonald EM, de Kock J, Ram FS. Antivirals for management of herpes zoster including ophthalmicus: a systematic review of high-quality randomized controlled trials. Antivir Ther. 2012;17(2):255–264. doi: 10.3851/IMP2011
   PubMed Web of Science ®Google Scholar
• Gross GE, Eisert L, Doerr HW, et al. S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia. J Dtsch Dermatol Ges. 2020;18(1):55–78. doi: 10.1111/ddg.14013
   Web of Science ®Google Scholar
• Poirrier JE, DeMartino JK, Nagar S, et al. Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination. Hum Vaccin Immunother. 2022;18(5):2040328. doi: 10.1080/21645515.2022.2040328
   PubMed Web of Science ®Google Scholar
• Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLOS Med. 2005;2(7):e164. doi: 10.1371/journal.pmed.0020164
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics. Varivax®. Varicella Virus Vaccine Live. 2022. [cited 2023 Sept 23]. Available from: https://www.medicines.org.uk/emc/product/5582/smpc
   Google Scholar
• European Medicines Agency. Zostavax: Summary of product characterstics. 2009. [cited 2023 Sept 23]. Available from. https://www.ema.europa.eu/en/documents/product-information/zostavax-epar-product-information_en.pdf
   Google Scholar
• Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922–928. doi: 10.1093/cid/cir970
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–2284. doi: 10.1056/NEJMoa051016
   PubMed Web of Science ®Google Scholar
• Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900–909. doi: 10.1093/cid/ciu918
   PubMed Web of Science ®Google Scholar
• ZOSTAVAX® (Zoster Vaccine Live). Product information. 2006. [cited 2024 Feb 21]. Available from: https://www.fda.gov/media/119879/download
   Google Scholar
• Litt J, Booy R, Bourke D, et al. Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine. Hum Vaccin Immunother. 2020;16(12):3081–3089. doi: 10.1080/21645515.2020.1754702
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kuyumdzhieva G, et al. Impact of the herpes zoster vaccination programme on hospitalised and general practice consulted herpes zoster in the 5 years after its introduction in England: a population-based study. BMJ Open. 2020;10(7):e037458. doi: 10.1136/bmjopen-2020-037458
   PubMed Web of Science ®Google Scholar
• Martins D, McCormack D, Tadrous M, et al. Impact of a publicly funded herpes zoster immunization program on the burden of disease in Ontario, Canada: a population-based study. Clin Infect Dis. [2021 Jan 27];72(2):279–284. doi: 10.1093/cid/ciaa014
   PubMed Web of Science ®Google Scholar
• Mbinta JF, Nguyen BP, Awuni PMA, et al. Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis. Lancet Healthy Longev. 2022;3(4):e263–e275. doi: 10.1016/S2666-7568(22)00039-3
   PubMedGoogle Scholar
• Lecrenier N, Beukelaers P, Colindres R, et al. Development of a recombinant adjuvanted herpes zoster subunit vaccine and its implications for shingles prevention. Expert Rev Vaccines. 2018;17(7):619–634. doi: 10.1080/14760584.2018.1495565
   PubMed Web of Science ®Google Scholar
• Orru S, Bierbaum S, Enk A, et al. Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020. Euro Surveill. 2023;28(50). doi: 10.2807/1560-7917.ES.2023.28.50.2300261
   PubMedGoogle Scholar
• Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–1032. doi: 10.1056/NEJMoa1603800
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Eng J Med. 2015;372(22):2087–2096. doi: 10.1056/NEJMoa1501184
   PubMed Web of Science ®Google Scholar
• Strezova A, Diez-Domingo J, Al Shawafi K, et al. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect Dis. 2022;9(10):ofac485. doi: 10.1093/ofid/ofac485
   PubMed Web of Science ®Google Scholar
• Fiore J, Co-van der Mee MM, Maldonado A, et al. Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance. Ther Adv Vaccines Immunother. 2021;9:25151355211057479. doi: 10.1177/25151355211057479
   Google Scholar
• Racine E, Gilca V, Amini R, et al. A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49 year old patients. Vaccine. 2020;38(40):6205–6214. doi: 10.1016/j.vaccine.2020.07.049
   PubMed Web of Science ®Google Scholar
• Lopez-Fauqued M, Co-van der Mee M, Bastidas A, et al. Safety profile of the adjuvanted recombinant zoster vaccine in immunocompromised populations: an overview of six trials. Drug Saf. 2021;44(7):811–823. doi: 10.1007/s40264-021-01076-w
   PubMed Web of Science ®Google Scholar
• Mullane KM, Morrison VA, Camacho LH, et al. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2019;19(9):1001–1012. doi: 10.1016/S1473-3099(19)30310-X
   PubMed Web of Science ®Google Scholar
• Dagnew AF, Rausch D, Herve C, et al. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford). 2021;60(3):1226–1233. doi: 10.1093/rheumatology/keaa424
   PubMed Web of Science ®Google Scholar
• Sun Y, Kim E, Kong CL, et al. Effectiveness of the recombinant zoster vaccine in adults aged 50 and older in the United States: a claims-based cohort study. Clin Infect Dis. 2021;73(6):949–956. doi: 10.1093/cid/ciab121
   PubMed Web of Science ®Google Scholar
• Sun Y, Jackson K, Dalmon CA, et al. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: a retrospective cohort study. Vaccine. 2021;39(29):3974–3982. doi: 10.1016/j.vaccine.2021.05.056
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Wu X, Forshee R, et al. Recombinant zoster vaccine (shingrix): real-world effectiveness in the first 2 years post-licensure. Clin Infect Dis. 2021;73(6):941–948. doi: 10.1093/cid/ciab125
   PubMed Web of Science ®Google Scholar
• Lu A, Sun Y, Porco TC, et al. Effectiveness of the recombinant zoster vaccine for herpes zoster ophthalmicus in the United States. Ophthalmol. 2021;128(12):1699–1707. doi: 10.1016/j.ophtha.2021.04.017
   PubMed Web of Science ®Google Scholar
• Parameswaran GI, Wattengel BA, Chua HC, et al. Increased stroke risk following herpes zoster infection and protection with zoster vaccine. Clin Infect Dis. 2022;76(3):e1335–e1340. doi: 10.1093/cid/ciac549
   Web of Science ®Google Scholar
• Kochhar GS, Desai A, Caldera DF, et al. Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease. Vaccine. 2021;39(30):4199–4202. doi: 10.1016/j.vaccine.2021.05.043
   PubMed Web of Science ®Google Scholar
• Bruxvoort KJ, Qian L, Wu J, et al. Herpes zoster following recombinant zoster vaccine with or without concomitant vaccination. Open Forum Infect Dis. 2022;9(3):ofac011. doi: 10.1093/ofid/ofac011
   PubMed Web of Science ®Google Scholar
• Laupeze B, Del Giudice G, Doherty MT, et al. Vaccination as a preventative measure contributing to immune fitness. NPJ Vaccin. 2021;6(1):93. doi: 10.1038/s41541-021-00354-z
   PubMed Web of Science ®Google Scholar
• Bruxvoort KJ, Ackerson B, Sy LS, et al. Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults. J Infect Dis. 2022;225(11): 1915–1922. doi:10.1093/infdis/jiab633
   PubMed Web of Science ®Google Scholar
• Belgian Superior Health Council. Vaccination against herpes zoster. Report 9684. (Brussels: SCH). 2022. [cited 2023 Sept 23]. Available from: https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/20220906_shc-9684_herpes_zoster_vweb.pdf
   Google Scholar
• Centre Belge d’Information Pharmacothérapeutique (CBIP). Folia Pharmacotherapeutica novembre 2023. 2023;50(11): 1–9. [cited 2023 Nov 24]. Available from: https://www.bcfi.be/nl/articles/query?number=F50N11I#zon
   Google Scholar
• Tricco AC, Zarin W, Cardoso R, et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ. 2018;363:k4029. doi: 10.1136/bmj.k4029
   PubMedGoogle Scholar
• Gobert C, Semaille P, Van der Schueren T, et al. Prevalence and determinants of vaccine hesitancy and vaccines recommendation discrepancies among general practitioners in French-speaking parts of Belgium. Vaccines (Basel). 2021;9(7):771. doi: 10.3390/vaccines9070771
   PubMed Web of Science ®Google Scholar
• Pattyn J, Hendrickx G, Valckx S, et al. Studie over vaccinatie vertrouwen voor het vaccinatiebeleid in Vlaanderen - Een observationele, crosssectionele online vragenlijst om vaccinatie vertrouwen in Vlaanderen te meten OVERHEIDSOPDRACHT: BESTEK NR AP/IZ-VAC/2023/62023. [cited 2024 Apr 11]. https://laatjevaccineren.paddlecms.net/sites/default/files/2024-02/Rapport%20VCF%20overheidsopdracht%20NR%20APIZ-VAC20236.pdf
   Google Scholar
• Wang Q, Yang L, Li L, et al. Willingness to vaccinate against herpes zoster and its associated factors across who regions: global systematic review and meta-analysis. JMIR Public Health Surveill. 2023;9:e43893. doi: 10.2196/43893
   PubMedGoogle Scholar
• Drolet M, Zhou Z, Sauvageau C, et al. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study. CMAJ. 2019;191(34):E932–E939. doi: 10.1503/cmaj.190274
   PubMed Web of Science ®Google Scholar
• Lehmann BA, Eilers R, Mollema L, et al. The intention of Dutch general practitioners to offer vaccination against pneumococcal disease, herpes zoster and pertussis to people aged 60 years and older. BMC Geriatr. 2017;17(1):122. doi: 10.1186/s12877-017-0511-7
   PubMedGoogle Scholar
• Hurley LP, Harpaz R, Daley MF, et al. National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine. J Infect Dis. 2008;197(Suppl 2):S216–23. doi: 10.1086/522153
   PubMedGoogle Scholar
• Hurley LP, Allison MA, Dooling KL, et al. Primary care physicians’ experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV). Vaccine. 2018;36(48):7408–7414. doi: 10.1016/j.vaccine.2018.09.018
   PubMed Web of Science ®Google Scholar
• Parikh R, Widenmaier R, Weller R, et al. An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine. Abstract. 15th European Public Health Conference 2022; Berlin, Germany; 2022.
   Google Scholar
• Belgian Superior Health Council. Publication of the Superior Health Council. Report 9158. Brussels: SHC. 2019. [cited 2023 Sept 23]. Available from: https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/20200212_shc_9158_ic_and_vaccination_vweb.pdf
   Google Scholar
• Andreoni M, Sticchi L, Nozza S, et al. Recommendations of the Italian society for infectious and tropical diseases (SIMIT) for adult vaccinations. Hum Vaccin Immunother. 2021;17(11):4265–4282. doi: 10.1080/21645515.2021.1971473
   PubMed Web of Science ®Google Scholar
• Ministerio de Sanidad. Recomendaciones de vacunacio n frente a herpes zoster, 25 marzo 2021. [cited 2023 Aug 1]. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/programasDeVacunacion/docs/HerpesZoster_RecomendacionesVacunacion.pdf
   Google Scholar
• Curran D, Patterson B, Varghese L, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36(33):5037–5045. doi: 10.1016/j.vaccine.2018.07.005
   PubMed Web of Science ®Google Scholar
• de Boer PT, van Lier A, de Melker H, et al. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines. BMC Med. 2018;16(1):228. doi: 10.1186/s12916-018-1213-5
   PubMedGoogle Scholar
• Van Oorschot D, Anastassopoulou A, Poulsen Nautrup B, et al. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old. Hum Vaccin Immunother. 2019;15(1):34–44. doi: 10.1080/21645515.2018.1509645
   PubMed Web of Science ®Google Scholar
• You JHS, Ming WK, Tsang OT, et al. Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults. PLOS ONE. 2019;14(1):e0210005. doi: 10.1371/journal.pone.0210005
   PubMed Web of Science ®Google Scholar
• McGirr A, Van Oorschot D, Widenmaier R, et al. Public health impact and cost-effectiveness of non-live adjuvanted recombinant zoster vaccine in Canadian adults. Appl Health Econ Health Policy. 2019 ;17(5):723–732. doi: 10.1007/s40258-019-00491-6
   PubMed Web of Science ®Google Scholar
• Curran D, Van Oorschot D, Matthews S, et al. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. Hum Vaccin Immunother. 2021;17(12):5296–5303. doi: 10.1080/21645515.2021.2002085
   PubMed Web of Science ®Google Scholar
• Ultsch B, Weidemann F, Koch J, et al. Modellierung von epidemiologischen und gesundheitsökonomischen: Effekten von impfungen zur prävention von herpes zoster. 2017 [cited 2023 Sept 21]. Available from: https://www.rki.de/DE/Content/Infekt/Impfen/ImpfungenAZ/Zoster/Modellierung_Zoster_Impfung.pdf?__blob=publicationFile
   Google Scholar
• Ortega-Sanchez I. Economics of vaccinating immunocompromised 19–49-years-old adults against herpes zoster in the US.September 29, 2021; ACIP zoster vaccines session. [cited 2023 Aug 21]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-09-29/02-ZosterVaccines-OrtegaSanchez-508.pdf
   Google Scholar
• Curran D, Patterson BJ, Carrico J, et al. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Hum Vaccin Immunother. 2023;19(1):2167907. doi: 10.1080/21645515.2023.2167907
   PubMed Web of Science ®Google Scholar
• Simoens S, Abdallah K, Barbier L, et al. How to balance valuable innovation with affordable access to medicines in Belgium? Front Pharmacol. 2022;13:960701. doi: 10.3389/fphar.2022.960701
   PubMed Web of Science ®Google Scholar
• Recommendation for a council recommendation on the 2023 national reform programme of Belgium and delivering a council opinion on the 2023 stability programme of Belgium. Brussels, 24 5.2023 COM(2023) 601 final. [cited 2023 Aug 21]. Available from: https://commission.europa.eu/system/files/2023-05/COM_2023_601_1_EN.pdf
   Google Scholar
• Bastidas A, de la Serna J, El Idrissi M, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123–133. doi: 10.1001/jama.2019.9053
   PubMed Web of Science ®Google Scholar
• Doherty TM, Del Giudice G, Maggi S. Adult vaccination as part of a healthy lifestyle: moving from medical intervention to health promotion. Ann Med. 2019;51(2):128–140. doi: 10.1080/07853890.2019.1588470
   PubMed Web of Science ®Google Scholar
• Talbird SE, La EM, Carrico J, et al. Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States. Hum Vaccin Immunother. 2021;17(2):332–343. doi: 10.1080/21645515.2020.1780847
   PubMed Web of Science ®Google Scholar
• Doherty TM, Pasquale AD, Finnegan G, et al. Sustaining the momentum for adult vaccination post-COVID-19 to leverage the global uptake of life-course immunisation: a scoping review and call to action. Int J Infect Dis. 2024;142:106963. doi: 10.1016/j.ijid.2024.02.006
   PubMed Web of Science ®Google Scholar